Navigation Links
EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers
Date:1/23/2008

(endometrium). The American Cancer Society estimates that there will be approximately 39,000 new cases of cancer of the uterine body diagnosed in the U.S. in 2007, resulting in approximately 7,400 deaths. There are currently four basic types of treatment for endometrial cancer including surgery, radiation, hormone therapy, and chemotherapy, of which surgery is the most common treatment.

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. MKC-1 is currently in multiple Phase 2 clinical trials for cancer. MKC-1 is an oral cell-cycle regulator with activity against the mTOR pathway. Panzem(R) (2-methoxyestradiol) NCD is also in multiple Phase 2 studies in oncology patients. Additionally, ENMD-1198, a novel tubulin-binding agent, is in Phase 1 studies in advanced cancers. The Company has approved IND applications for Panzem(R) in rheumatoid arthritis, and ENMD-2076, a dual-acting Aurora- angiogenesis inhibitor, for cancer. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell-cycle regulation and inflammation - processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company's web site at http://www.entremed.com and in various filings with the Securities and Exchange Commission.

Forward Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance (including the timing of royalty revenues and future R&D expenditures), strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forw
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
2. EntreMed Raises $20 Million to Support Clinical Development Program
3. EntreMed Reports Phase 1 PK and Preclinical Efficacy Results for ENMD-1198
4. EntreMed Shows Increased Survival With MKC-1 in Preclinical Renal Cell Cancer Model
5. EntreMed Commences Phase 2 Study with MKC-1 in Pancreatic Cancer
6. EntreMed to Present at The New York Society of Security Analysts Industry Conference
7. Memory Pharmaceuticals Commences Phase 1 Clinical Program for R4996/MEM 63908
8. Sinovac Commences Vaccination on Volunteers for Phase II Clinical Trial on Pandemic Influenza H5N1 Vaccine
9. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
10. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
11. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 2014 HeartWare International, Inc . (NASDAQ: ... miniaturized circulatory support technologies that are revolutionizing the treatment ... revenues for the fourth quarter of 2013 will be ... approximately $208 million. "Our full-year revenue growth ...
(Date:1/14/2014)... , Jan. 14, 2014 InformEx, North ... sellers of high-value chemistry, will hold the 30 th ... Beach Convention Center from January 21-24. ... attendees from top pharmaceutical, fine chemical and specialty chemical companies ...
(Date:1/14/2014)... Dynamic Healthcare Services, Inc. ("DHS"), a portfolio company of GMH ... Medical Equipment, Inc. ("Progressive") of Clarion, PA ... were not disclosed. Progressive is a full ... of sleep, mobility, and respiratory products to customers in the ...
Breaking Medicine Technology:HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3
... MYL ) today announced that it has notified The ... (Nasdaq: NDAQ ), that it intends to voluntarily de-list ... Market, on which the notes trade under the ticker symbol "MYLNG," ... The notes will continue to trade over-the-counter (OTC) with trade data ...
... Ultra Clean Holdings, Inc. (Nasdaq: UCTT ), ... semiconductor capital equipment, medical device, energy, research, and flat ... Executive Officer, and Casey Eichler, Chief Financial Officer, will ... will take place at the New York Palace Hotel, ...
Cached Medicine Technology:Mylan Announces Voluntary De-listing of 1.25% Senior Convertible Notes Due 2012 from Nasdaq 2
(Date:4/24/2014)... long thought to be boring and irrelevant, could offer ... disease. , Researcher Dr Milena Furtado, and her team ... University, found the heart cell fibroblast is a close ... healthy beating heart. , In research published today in ... cardiac fibroblasts are unique cells due to their genetic ...
(Date:4/24/2014)... one out of three survivors of critical illness, ... The Lancet Respiratory Medicine , and the majority ... mentally. , It is one of the largest ... outcomes of critical care survivors, according to lead ... and it highlights a significant public health issue, ...
(Date:4/24/2014)... NH, 4/24/14) Dartmouth has been awarded one of ... serve as a Lead Academic Participating Site in its ... Award recipients are a select groups of investigators charged ... fewer cooperative groups., The NCTN grant system reflects recommendations ... It streamlines operations to achieve four goals:, ...
(Date:4/24/2014)... In 2009 the influenza pH1N1 virus caused the first ... Finland in May 2009 and killed more than 50 ... infects Finns mainly during flu epidemics (winter/spring seasons). ... to serious complicated illnesses. World Health Organization has recommended ... illness. The disadvantage of this drug is that it ...
(Date:4/23/2014)... was safe and effective in treating patients with ... , according to a new pilot study published ... online. Known as fecal microbiota transplantation, the treatment ... or a nasogastric tube. The findings suggest approaches ... available to patients. , A growing concern, ...
Breaking Medicine News(10 mins):Health News:Boring cells could hold the key to heart disease 2Health News:Vanderbilt study finds physical signs of depression common among ICU survivors 2Health News:Vanderbilt study finds physical signs of depression common among ICU survivors 3Health News:Dartmouth awarded lead role in NCI clinical trials network 2Health News:Dartmouth awarded lead role in NCI clinical trials network 3Health News:Pilot study suggests ways to widen access to fecal transplants for C. diff infections 2
... first time that coffee beans contain proteins that can kill ... food crops against destructive pests. Their study, which suggests a ... in the world, appears in ACS, Journal of Agricultural ... and some other plant seeds contain proteins, called globulins, which ...
... for Passover and year-round: With observant Jews numbering barely one ... are 40-50 percent of food items on supermarket shelves kosher? ... popularity of kosher foods appear in an article in ... C&EN Senior Editor Bethany Halford notes that the number ...
... it takes to get things done, research shows , WEDNESDAY, ... how long it will take to do something, don,t ask ... toward optimism and are less likely to make an accurate ... predictions much more than others, and their error rates can ...
... safety of increasingly popular imaging procedures such as virtual ... that popular medical imaging technologies are exposing Americans to ... week as the U.S. Food and Drug Administration concludes ... on how to increase the safety of these procedures. ...
... ... innovative, value-focused approach to streamline litigation and compliance management. Taking a proactive stance ... review team - cuts project costs substantially. , ... (PRWEB) March 31, 2010 -- HLP Integration (“HLP”) and Pat ...
... ... for Swimsuit Season. , ... (PRWEB) March 31, 2010 -- The Knowland Group , a leading provider ... 2010 Knowland Fitness Challenge. Designed to help employees improve their overall health and get ...
Cached Medicine News:Health News:Powerful People Often Too Optimistic About Task Time 2Health News:FDA Hears Views on Risks of High Tech Scanners 2Health News:FDA Hears Views on Risks of High Tech Scanners 3Health News:FDA Hears Views on Risks of High Tech Scanners 4Health News:HLP Integration and Pat Taylor and Associates, Inc. Announce a Project Alliance. 2Health News:Knowland Group Kicks Off Employee Fitness Challenge with Award-Winning Body Builder and Personal Trainer Dave Kergaard 2Health News:Knowland Group Kicks Off Employee Fitness Challenge with Award-Winning Body Builder and Personal Trainer Dave Kergaard 3
Pediatric model. Spring-controlled spread of blades with locking mechanism. Dull finish. Blades: 11 mm....
Fenestrated blades with screw-controlled spread. Dull finish. Blades: 15 mm....
Designed for use with foster enucleation snare (E3670). Package of 12 stainless steel wires. Overall length 5.3 inches....
IOL explanation snare for foldable lenses. Snare bisects lens for easy removal. Easy thumb activation. Replacement snares available E3526....
Medicine Products: